---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010964"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:21:25.654131+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CSO and VP Regulatory resign; shareholders authorize reverse split and large issuances

## Summary
- Dr. Anatoly Dritschilo resigned as CSO and director effective May 9, 2025; no disagreement cited.
- Michael P. Vander Hoek resigned as VP Regulatory effective June 10, 2025; no disagreement cited.
- Shareholders approved reverse stock split at ratio from 1-for-3 to 1-for-100.
- Approved increase in equity plan shares by 5,000,000 and issuances of >19.99% stock on note conversion.
- Approved issuances of >20% stock on convertible preferred offering and equity line of credit.

## SEC filing metadata
- accession: 0001641172-25-010964
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000164117225010964/0001641172-25-010964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000164117225010964/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010964
- JSON: https://secwatch.observer/filing/0001641172-25-010964.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010964.txt

## Source-grounded claims
- claim_id: 04c846d77a
  claim: Michael P. Vander Hoek resigned as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: On May 9, 2025, Michael P. Vander Hoek submitted his resignation from the position of Vice President, Regulatory, of the Company, effective June 10, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000164117225010964/0001641172-25-010964-index.htm
- claim_id: a427c5749f
  claim: Dr. Anatoly Dritschilo resigned as Chief Scientific Offer and director at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: On May 9, 2025, Dr. Anatoly Dritschilo, resigned as Chief Scientific Offer and director of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000164117225010964/0001641172-25-010964-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.